Compare Stocks

Date Range: 

 EvolusCytomX TherapeuticsForte BiosciencesMolecular TemplatesTherapeuticsMD
SymbolNASDAQ:EOLSNASDAQ:CTMXNASDAQ:FBRXNASDAQ:MTEMNASDAQ:TXMD
Price Information
Current Price$9.14$8.55$32.64$8.81$1.09
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.51.61.72.01.5
Analysis Score4.33.43.53.43.2
Community Score2.82.83.52.62.6
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.83.30.8
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$15.00$12.07$82.00$14.50$5.07
% Upside from Price Target64.11% upside41.19% upside151.23% upside64.59% upside364.83% upside
Trade Information
Market Cap$399.77 million$555.78 million$441.03 million$494.14 million$428.58 million
Beta2.690.740.232.082.19
Average Volume1,458,2751,069,368176,442443,70013,368,902
Sales & Book Value
Annual Revenue$34.92 million$57.49 million$40,000.00$22.27 million$49.65 million
Price / Sales11.459.6711,025.7922.198.63
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.38 per share$1.12 per share$6.81 per share$2.79 per share$0.03 per share
Price / Book3.847.634.793.1636.33
Profitability
Net Income$-90,030,000.00$-102,240,000.00$-63,520,000.00$-69,420,000.00$-176,150,000.00
EPS($3.19)($2.26)($40.33)($1.26)($0.68)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-120.63%-58.13%N/A-428.65%-327.98%
Return on Equity (ROE)-121.11%-94.20%-417.87%-111.43%N/A
Return on Assets (ROA)-30.91%-13.79%-248.28%-56.35%-78.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.25%N/AN/A0.18%N/A
Current Ratio10.42%3.34%8.97%3.21%2.59%
Quick Ratio10.03%3.34%8.97%3.21%2.38%
Ownership Information
Institutional Ownership Percentage21.66%77.87%53.03%60.73%52.56%
Insider Ownership Percentage10.10%5.80%10.90%38.20%13.76%
Miscellaneous
Employees1191449228400
Shares Outstanding43.74 million65.00 million13.51 million56.09 million393.19 million
Next Earnings Date5/12/2021 (Confirmed)8/5/2021 (Estimated)5/10/2021 (Confirmed)5/10/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
TherapeuticsMD (NASDAQ:TXMD) Announces  Earnings Results, Misses Expectations By $0.01 EPSTherapeuticsMD (NASDAQ:TXMD) Announces Earnings Results, Misses Expectations By $0.01 EPS
americanbankingnews.com - May 8 at 2:58 PM
TherapeuticsMD Inc (TXMD) Up 5.41% in Premarket Trading - InvestorsObserverTherapeuticsMD Inc (TXMD) Up 5.41% in Premarket Trading - InvestorsObserver
investorsobserver.com - May 8 at 12:21 PM
TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - Yahoo FinanceTherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - Yahoo Finance
finance.yahoo.com - May 7 at 3:38 PM
TherapeuticsMD Announces First Quarter 2021 Financial Results - BioSpaceTherapeuticsMD Announces First Quarter 2021 Financial Results - BioSpace
biospace.com - May 7 at 10:38 AM
TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript - Motley FoolTherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 7 at 10:38 AM
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceTherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 7 at 10:38 AM
TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call TranscriptTherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript
fool.com - May 7 at 1:39 AM
TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - BenzingaTherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - Benzinga
benzinga.com - May 7 at 12:37 AM
TherapeuticsMD: Q1 Earnings Snapshot - SFGateTherapeuticsMD: Q1 Earnings Snapshot - SFGate
sfgate.com - May 6 at 7:37 PM
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - NasdaqTherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
nasdaq.com - May 6 at 2:36 PM
How Will the Market React to TherapeuticsMD Inc (TXMD) Stock Getting a Bullish Rating - InvestorsObserverHow Will the Market React to TherapeuticsMD Inc (TXMD) Stock Getting a Bullish Rating - InvestorsObserver
investorsobserver.com - May 6 at 2:36 PM
TherapeuticsMD drops 3% despite consensus beating Q1 results - Seeking AlphaTherapeuticsMD drops 3% despite consensus beating Q1 results - Seeking Alpha
seekingalpha.com - May 6 at 2:36 PM
TherapeuticsMD: Q1 Earnings Snapshot - Westport NewsTherapeuticsMD: Q1 Earnings Snapshot - Westport News
westport-news.com - May 6 at 2:36 PM
TherapeuticsMD Announces First Quarter 2021 Financial ResultsTherapeuticsMD Announces First Quarter 2021 Financial Results
finance.yahoo.com - May 6 at 2:36 PM
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue EstimatesTherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 2:36 PM
TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription VolumeTherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume
finance.yahoo.com - May 6 at 2:36 PM
TherapeuticsMD (NASDAQ:TXMD) Shares Gap Down to $1.28TherapeuticsMD (NASDAQ:TXMD) Shares Gap Down to $1.28
americanbankingnews.com - May 6 at 1:34 PM
A Preview Of TherapeuticsMDs Earnings - BenzingaA Preview Of TherapeuticsMD's Earnings - Benzinga
benzinga.com - May 5 at 11:07 AM
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Yahoo FinanceTherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Yahoo Finance
finance.yahoo.com - May 5 at 11:07 AM
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business WireTherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business Wire
businesswire.com - May 3 at 8:52 AM
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual MeetingTherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
finance.yahoo.com - May 3 at 8:52 AM
TherapeuticsMD (TXMD) to Release Quarterly Earnings on ThursdayTherapeuticsMD (TXMD) to Release Quarterly Earnings on Thursday
americanbankingnews.com - April 30 at 10:37 AM
TherapeuticsMDs (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares - Yahoo FinanceTherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares - Yahoo Finance
finance.yahoo.com - April 29 at 5:51 PM
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021 - Yahoo FinanceTherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021 - Yahoo Finance
finance.yahoo.com - April 29 at 5:51 PM
TherapeuticsMDs (NASDAQ:TXMD) Shareholders Are Down 85% On Their SharesTherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares
finance.yahoo.com - April 29 at 5:51 PM
DateCompanyBrokerageAction
5/6/2021EvolusMizuhoUpgrade
4/14/2021EvolusHC WainwrightReiterated Rating
2/24/2021EvolusTruist FinancialDowngrade
2/22/2021EvolusBarclaysBoost Price Target
2/22/2021EvolusCantor FitzgeraldBoost Price Target
2/19/2021EvolusStifel NicolausBoost Price Target
7/7/2020EvolusSunTrust BanksLower Price Target
4/30/2020EvolusWells Fargo & CompanyLower Price Target
3/29/2021CytomX TherapeuticsJefferies Financial GroupUpgrade
3/29/2021CytomX TherapeuticsJPMorgan Chase & Co.Initiated Coverage
9/22/2020CytomX TherapeuticsGuggenheimDowngrade
9/15/2020CytomX TherapeuticsCitigroupLower Price Target
5/17/2020CytomX TherapeuticsNomuraReiterated Rating
3/24/2020CytomX TherapeuticsWedbushUpgrade
2/28/2020CytomX TherapeuticsNomura SecuritiesLower Price Target
4/1/2021Forte BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/26/2021Forte Biosciences(FBRC)Initiated Coverage
3/23/2021Forte BiosciencesChardan CapitalLower Price Target
8/28/2020Forte BiosciencesBrookline Capital ManagementInitiated Coverage
8/25/2020Forte BiosciencesTruist SecuritiInitiated Coverage
6/22/2020Forte BiosciencesLADENBURG THALM/SH SHInitiated Coverage
4/27/2021Molecular TemplatesBank of AmericaInitiated Coverage
4/15/2021Molecular TemplatesOppenheimerLower Price Target
2/1/2021Molecular TemplatesUBS GroupInitiated Coverage
11/13/2019Molecular TemplatesCowenReiterated Rating
12/11/2018Molecular TemplatesCIBCInitiated Coverage
11/15/2018Molecular TemplatesEvercore ISIInitiated Coverage
10/8/2018Molecular TemplatesLaidlawInitiated Coverage
7/22/2020TherapeuticsMDNoble FinancialReiterated Rating
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.